Where a single Phase 2 data readout can reprice the float 60% in a morning and a CRL can halve it by lunch. Our beat is sub-$500M drug developers, clinical-stage platforms, and the dilution math that sell-side decks quietly leave out.
Dyadic (DYAI) revenue rose 182% to $1.11M in Q1 2026, but stockholders' equity went negative and the newest deal names…
Picard Medical completed a successful preclinical implant series of its next-gen Emperor artificial heart.
Adagene has a new Incyte cancer collaboration and about $128M in cash. Validation plus a long runway.
Biomea showed icovamenib diabetes data at ADA and is advancing BMF-650, with an obesity readout due in Q3.
Cardiff Oncology showed Phase 2 onvansertib data at ASCO and picked a 30mg dose for a planned Phase 3 in colon cancer.
Kazia expanded its paxalisib breast-cancer trial and holds ~$46M, enough to fund operations into 2029.
Jaguar Health launched a strategic review of crofelemer amid heavy financing activity. Capital structure is the story.
Precision's ELIMINATE-B biopsy data show its editor cutting hepatitis B cccDNA, with HBsAg declines in all patients.
Spain's AEMPS cleared Theriva's VIRAGE2 trial to test more frequent VCN-01 dosing in pancreatic cancer.
Corbus named an oncology CMO before its CRB-913 obesity readout and a registrational cancer trial. The hire is a tell.
How masked-antibody design aims to spare healthy tissue in cancer immunotherapy.
Why covalent, irreversible small-molecule binding is having a quiet renaissance.
Why a 50-year treatment plateau in glioblastoma is finally showing cracks.
In vivo gene editing as the next frontier after CRISPR-Cas9.
A different approach to chronic-disease treatment through implantable delivery.
The biology behind KRAS-mutated colorectal cancer and how investors should read the trial data.
The total artificial heart as an underappreciated bridge to transplant — the need and the market.
Ameluz revenue growing high-teens. OpEx flat. Sales-force buildout finally scaling. The textbook commercial-stage inflection — just without the story-stock drama.
Clearmind finished dosing all 24 Part A participants of CMND-100 for alcohol use disorder. The topline data is the next question.
FDA alignment derisks the most common reason Phase 3 trials fail. What Corbus does with the compressed calendar is the whole equity story.
Crofelemer's canine CID trial is the first real platform-extension shot. Human vs. veterinary economics are not the same model.
Phase 2b oncolytic-virus data at AACR. But the balance sheet is what actually moves the equity — cash runway analysis and three financing paths.
Biofrontera grew Q1 revenue 17% and had its Ameluz basal-cell-carcinoma filing accepted by the FDA. Going-concern is the catch.